pembrolizumab
merck
['keynote 412', 'pembro']
pembro plus ctrt f/by pembro maintenance. numerically better efs . not statistically significant. no improvement in os . keynote 412 . negative study . #esmo22 
Oncology care , to give or not to give chemo , data analysis , oncology pharamocovigilance , enthusiastic critic, twitts are not twists